Gilead Keeps on Building

In the following video, Motley Fool health-care analyst David Williamson discusses a new E.U. approval for Gilead (NASDAQ: GILD  ) for its quad pill HIV drug cocktail, which has shares up 2% to near all-time highs. David tells investors why this is just one more piece to the puzzle for Gilead, as it continues to build its empire in the treatment of HIV.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2328419, ~/Articles/ArticleHandler.aspx, 7/28/2014 7:30:54 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement